Bioactivity | (Rac)-Cemsidomide ((Rac)-CFT7455) is a zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) degrader, acting via the ubiquitin proteasome pathway, with a GI50 of 0.05 nM for NCIH929.1 cells. (Rac)-Cemsidomide is the racemic isomer of Cemsidomide (HY-144841A) which is a IKZF1/IKZF3 degrader with anticancer activity[1][2]. | ||||||||||||
Target | Ikaros, Aiolos | ||||||||||||
Name | (Rac)-Cemsidomide | ||||||||||||
CAS | 2504233-68-3 | ||||||||||||
Formula | C28H27N3O4 | ||||||||||||
Molar Mass | 469.53 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. David Proia et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1 (compound 5) [2]. James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement): LB007. |